Keros Therapeutics, Inc. announced the appointment of Yung H. Chyung, M.D., as its new Chief Medical Officer, effective October 16, 2024. Dr. Chyung will be responsible for overseeing the company's clinical development programs. This executive appointment is expected to strengthen Keros' leadership in advancing its pipeline of novel therapeutics.
The company is a clinical-stage biopharmaceutical firm focused on developing treatments for disorders linked to dysfunctional signaling of the TGF-ß family of proteins. Dr. Chyung's expertise will be vital as Keros progresses its product candidates through various clinical trial stages. His role is central to ensuring the scientific and regulatory integrity of Keros' investigational therapies.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.